Portal de Periódicos da CAPES

Rapid Loss of Specific Antibodies after Pneumococcal Vaccination in Patients with Human Immunodeficiency Virus-1 Infection

1998; Informa; Volume: 30; Issue: 6 Linguagem: Inglês

10.1080/00365549850161160

1651-1980

Henriette Svarre Nielsen, Birgit Kvinesdal, Thomas Benfield, Jens Lundgren, Helle Bossen Konradsen,

Pneumocystis jirovecii pneumonia detection and treatment

Pneumococcal infections are frequently observed in patients with human immunodeficiency virus (HIV) infection and active immunization has been recommended as prophylaxis in this patient group. We studied 103 out-patients with asymptomatic or mildly symptomatic HIV infection with respect to specific IgG and IgG2 pneumococcal antibodies before and after vaccination with a 23-valent pneumococcal polysaccharide vaccine. A significant increase ( > 2-fold) in IgG and IgG2 antibody levels was observed after 1 month in 69/103 patients (67%) with no correlation with the CD4 cell count at the time of vaccination. The response rate was not influenced by concurrent treatment with anti-retroviral monotherapy, or by age or gender. After immunization a strong correlation between IgG and IgG2 anti-pneumococcal antibodies was demonstrated. Nevertheless, 12 months after vaccination the specific antibody titres were not significantly different from pre-vaccination values. In conclusion, antibodies induced by pneumococcal vaccination in patients with HIV infection have a short duration. This raises the question as to whether vaccination will have any impact on clinical end-point in this group of patients.